CVE-2024-10476

highPriorität · verfolgen · 0OT-Risiko · erhöhtEPSS 0.002 · 14. PerzentilEUUS
grimoire priorityP2 · Scheduled
Exploitable?
—
no known exploitation
Likely / severe?
0.24% (14th) EPSS
CVSS 8 · high
Is it mine?
18 products
Prüfe deine Angriffsfläche
Who says so?
3 sources
cnnvd · enisa_euvd · cisa_csaf_ot

EPSS · bewertet 2026-10-27

Default credentials are used in the above listed BD Diagnostic Solutions products. If exploited, threat actors may be able to access, modify or delete data, including sensitive information such as protected health information (PHI) and personally identifiable information (PII). Exploitation of this vulnerability may allow an attacker to shut down or otherwise impact the availability of the system. Note: BD Synapsys™ Informatics Solution is only in scope of this vulnerability when installed on a NUC server. BD Synapsys™ Informatics Solution installed on a customer-provided virtual machine or on the BD Kiestra™ SCU hardware is not in scope.

01

Behebungen

Hersteller-Fix, Mitigation oder Workaround, wie von den Quellen veröffentlicht.

Ein Hersteller-Fix ist verfügbar.

  • BehobenBD Synapsys Informatics Solutioncisa_csaf_ot

    Note: BD Synapsys Informatics Solution is only in scope of this vulnerability when installed on a NUC server. BD Synapsys Informatics Solution installed on a user-provided virtual machine or on the BD Kiestra SCU hardware is not in scope.

  • MitigationBD BACTEC Blood Culture Systemcisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

  • MitigationBD COR Systemcisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

  • MitigationBD EpiCenter Microbiology Data Management Systemcisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

  • MitigationBD MAX Systemcisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

  • MitigationBD Phoenix M50 Automated Microbiology Systemcisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

  • MitigationBD Synapsys Informatics Solutioncisa_csaf_ot

    BD has already communicated to users with affected products and is working with them to update default credentials on affected products. For this vulnerability to be exploited, a threat actor will need direct access, whether logical or physical, into the clinical setting.

02

cvss

Technischer Schweregrad, 0–10. Eine Zeile je Quelle.

8.0
010

Basiswert 0–10 · höher = schwerwiegender · Vektor überfahren zum Auflösen

v3.18highCVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:Hsecondary · CISA US
v3.18highCVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:Hsecondary · ENISA EU
v3.18highCVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:Hsecondary · cybersecurity@bd.comAusnutzbarkeit 2.1 · Auswirkung 5.9
v3.17.3highCVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H/E:Usecondary · CVSS-BT (t0sche)
03

SSVC

Eine Handlungsentscheidung — aus Ausnutzung und Auswirkung.

Exploitation: none · Automatable: no · Technical Impact: totalcoordinatorcisa_ssvcUS
04

schwächen

Die CWE-Schwächeklassen, zu denen dies gehört.

05

betroffene Produkte (18)

Betroffene Produkte und Versionsbereiche.

06

Advisories (1)

Hersteller- und Ökosystem-Meldungen dazu.

  • ICSMA-24-352-01BD Diagnostic Solutions Products (Update A)2024-12-17icsa · cisa_csaf_otUS

    Successful exploitation of this vulnerability could allow an attacker to use default credentials to access, modify, or delete sensitive data, which could impact the availability of the system or cause a system shutdown.

07

auch bekannt als (3)

Weitere Namen und Kennungen dieser Entität.

08

quellen

Welche Quellen diesen Datensatz belegen und wann.

veröffentlicht 2024-12-17geändert 2026-06-17
09

Referenzen (3)

Externe Belege — Patches, Meldungen, Analysen.

scry

Angreifer nutzen Schwachstellen wie diese gegen im Internet exponierte Dienste aus. Sehen Sie mit einem kostenlosen Passiv-Scan, was exponiert ist.

Kostenloser Scan